KALA BIO (KALA) Financials

Here are the key trends for Kala Bio (KALA) based on quarterly statements from the last four years. The focus is on profitability, liquidity, and balance-sheet health that matter to retail investors.

• Positive quarterly profitability (Q4 2025): Kala Bio reported net income attributable to common shareholders of $686,000 in Q4 2025, helped by notable non-operating income, signaling a rare quarterly gain despite ongoing operating losses.
• Low or zero long‑term debt (through Q3–Q1 2025): Long‑term debt is reported as 0 in Q3 2025 and in the surrounding quarters, reducing long‑term leverage risk.
• Liquidity from cash on hand (Q3 2025): Cash and cash equivalents were about $21.1 million, providing a cushion to fund near‑term activities.
• Access to equity financing (multiple quarters): Kala has repeatedly issued common equity in several quarters, boosting liquidity and helping to finance operations and capital needs.
• Positive financing activity in some periods: Net cash from financing activities was positive in certain quarters (indicating net capital inflows from equity financing), contributing to liquidity despite ongoing cash burn from operations.
• Revenue largely flat at zero: Across Q1–Q4 2025 (and prior years’ quarters shown), Total Revenue is essentially zero, suggesting no product sales yet and limited operating upside from the top line.
• Profitability driven by non‑operating items: Even when results show a quarterly net income, it’s largely due to non‑operating income, not core operating performance, indicating ongoing operating losses.
• Persistent quarterly net losses: Core results show sizable losses in many quarters (for example, Q3 2025 net income of about −$7.56 million), underscoring a continuing profitability challenge.
• Rising operating costs relative to revenue: Selling, General & Administrative and Research & Development expenses are frequently in the mid‑millions per quarter, far outpacing the minimal or zero revenue.
• Balance-sheet fragility and near‑term liquidity pressure: Negative equity is evident in several periods (e.g., negative total equity in Q3 2025), with notable short‑term debt levels (roughly in the $11–28 million range in recent quarters), signaling ongoing liquidity and solvency risk if financing or revenue growth slows.

Notes for context (high level): Revenue has stayed effectively flat at zero in the quarters shown, while operating expenses remain substantial. Cash burn from operations has been evident in multiple quarters, offset in part by equity financing and occasional non‑operating income. The company’s capital structure shows no long‑term debt in several periods, but short‑term liabilities and negative equity highlight ongoing balance‑sheet and liquidity considerations for investors. As always, consider how ongoing fundraising and any potential product milestones could influence Kala Bio’s financial trajectory moving forward.